Net Sales are expected to increase by 8.1 percent Q-o-Q (up 5.8 percent Y-o-Y) to Rs 542 crore, according to Centrum.
Drug firm Pfizer today reported a 6.47 per cent rise in standalone net profit to Rs 80.04 crore for the quarter ended June 30.
CNBC-TV18‘s Varinder Bansal gets you companies that have stood out in terms of outstanding Q3 numbers. The stocks on his radar for today are Lakshmi Machine Works, Pfizer & La Opala.
Pharma companies are likely to post 12 percent Y-o-Y revenue growth. However, excluding Wockhardt (FDA issues) and Fortis Healthcare (divestments), revenue growth is expected to be 19 percent Y-o-Y.
Kiran Mazumdar Shaw, CMD of Biocon said their branded formulation business has grown 45 percent and excluding it the bio pharma business has seen 20 percent growth year-on-year. She also feels the business is gaining traction in emerging markets and the US.
Pharma major Pfizer registered a net profit of Rs 48.10 crore in the fourth quarter of FY12 in comparison to Rs 63.14 crore in the corresponding quarter last fiscal.
India's largest listed biotechnology firm Biocon said on Thursday it would divest its stake in German unit AxiCorp, after roughly meeting estimates with a 25% rise in the fourth-quarter net profit.
Stride Arcolab announced it Q3 results for FY11. The company reported a consolidated net profit of Rs 122.4 crore for the year ended 2010 as against Rs 109.7 crore in previous year.
Speaking to CNBC-TV18, Kewal Handa, MD of Pfizer said the firm has planned multiple launches in 2011. "We expect to grow above market rates," he added.
Emkay Global Financial Services has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Pfizer December quarter sales are expected to go up by 11.1% to Rs 227.5 crore, Year-on-Year, (Y-o-Y) basis.